Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA
Ellipses Pharma announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its next generation selective RET inhibitor EP0031/A400 for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC). The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.
For more information:
Learn more about The Happy Lungs Supported RET Cancer research here.
